ProjectRHOligo – Translational development of antisense oligonucleotide-based therapies for autosomal dominant retinitis…
Basic data
Title:
RHOligo – Translational development of antisense oligonucleotide-based therapies for autosomal dominant retinitis pigmentosa
Duration:
01/06/2026 to 01/06/2027
Abstract / short description:
We are advancing a mutation-independent antisense oligonucleotide therapy for the treatment of RHO-associated retinitis pigmentosa (RHO-RP) toward clinical application. This includes Chemistry, Manufacturing and Controls development, GMP-compliant manufacturing, and GLP toxicology studies.
Involved staff
Managers
Department of Biology
Faculty of Science
Faculty of Science
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Research Center for Ophthalmology
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Tübingen, Baden-Württemberg, Germany